BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 33, Issue 19, 2015, Pages 2197-2204

  Zhou, Caicun ^a   Wu, Yi Long ^e   Chen, Gongyan ^g   Liu, Xiaoqing ^h   Zhu, Yunzhong ⁱ   Lu, Shun ^b   Feng, Jifeng ^l   He, Jianxing ^f   Han, Baohui ^b   Wang, Jie ^j   Jiang, Guoliang ^c   Hu, Chunhong ^m   Zhang, Hao ⁿ   Cheng, Gang ^k   Song, Xiangqun ^o   Lu, You ^p   Pan, Hongming ^q   Zheng, Wenjuan ^d   Yin, Anny Yue ^d  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI CHEST HOSPITAL   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d Roche China Ltd   (China)

^e GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^f GUANGZHOU MEDICAL UNIVERSITY   (China)

^g HARBIN MEDICAL UNIVERSITY   (China)

^h BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

ⁱ CAPITAL MEDICAL UNIVERSITY   (China)

^j PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^k BEIJING HOSPITAL   (China)

^l JIANGSU CANCER HOSPITAL   (China)

^m CENTRAL SOUTH UNIVERSITY   (China)

ⁿ CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^o GUANGXI MEDICAL UNIVERSITY   (China)

^p SICHUAN UNIVERSITY   (China)

^q ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ICOTINIB; PACLITAXEL; PEMETREXED; PLACEBO; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BACKACHE; BONE MARROW DEPRESSION; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HEART FAILURE; HUMAN; HYPERTENSION; LUNG INFARCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SMOKING; THROMBOCYTOPENIA; THROMBOEMBOLISM; WILD TYPE; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PLACEBOS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84937117699     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.4424     Document Type: Article

References (20)

1. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
2. Bareschino MA, Schettino C, Rossi A, et al: Treatment of advanced non small cell lung cancer. J Thorac Dis 3:122-133, 2011
3. Hotta K, Matsuo K, Ueoka H, et al: Addition of platinum-doublet compounds to a new agent in patients with advanced non-small-cell lung cancer: A literature-based meta-analysis of randomized trials. Ann Oncol 15:1782-1789, 2004
4. Klastersky J, Awada A: Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol 81:49-57, 2012
5. Xue C, Hu Z, Jiang W, et al: National survey of medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 77:371-375, 2012
6. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
7. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
8. Casaluce F, Sgambato A, Maione P, et al: ALK inhibitors: A new targeted therapy in the treatment of advanced NSCLC. Target Oncol 8:55-67, 2013
9. Thomas RK, Weir B, Meyerson M: Genomic approach to lung cancer. Clin Cancer Res 12:4384s-4391s, 2006
10. Paz-Ares L, Soulières D, Melezínek I, et al: Clinical outcomes in the non-small cell lung cancer patients with EGFR mutations: Pooled analysis. J Cell Mol Med 14:51-69, 2010
11. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253, 2009
12. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
13. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27:1227-1234, 2009
14. Mok T, Hsia T, Tsai CM, et al: Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small-cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial. Asia Pac J Clin Oncol 7:4-12, 2011
15. Tsai CM, Au JS, Chang GC, et al: Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: Results from the phase IV MO19390 (SAiL) study. J Thorac Oncol 6:1092-1097, 2011
16. Pharmaceuticals and Medical Devices Agency: Basic principles on Global Clinical Trials 2007. http://www.pmda.go.jp/kijunsakusei/file/guideline/new-drug/GlobalClinicalTrials-en.pdf
17. Crinò L, Dansin E, Garrido P, et al: Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): A phase 4 study. Lancet Oncol 11:733-740, 2010
18. Zhou C, Bai C, Guan Z, et al: Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: Data of subgroup analyses from MO19390 (SAiL) study. Clin Transl Oncol 16:463-468, 2014
19. Niho S, Kunitoh H, Nokihara H, et al: Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76:362-367, 2012
20. Soo RA, Loh M, Mok TS, et al: Ethnic differences in survival outcomes in patients with advanced stage non-small cell lung cancer. J Thorac Oncol 6:1030-1038, 2011